SCHEMBL901585

SCHEMBL901585

CCOC(=O)C(=O)C(Oc1ccc(Cl)c(F)c1)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
SLC6A4 P31645 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.37
FFAR1 O14842 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
PKM P14618 1/20 0.36
CASP1 P29466 1/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
ATF4 P18848 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901851 0.88 ALDH1A1 (0.46) PPARGPPARASLC6A4SMN1; SMN2TSHR
SCHEMBL17959956 0.83 PPARA (0.47) PPARGPPARASLC6A4SMN1; SMN2TSHR
SCHEMBL10899719 0.82 PPARA (0.47) PPARGPPARASMN1; SMN2TSHRALDH1A1
SCHEMBL10898655 0.79 KMT2A (0.48) PPARGPPARASMN1; SMN2ALDH1A1KMT2A
SCHEMBL913926 0.78 PPARG (0.47) PPARGPPARASLC6A4SMN1; SMN2TSHR
SCHEMBL6841936 0.76 LDHA (0.51) PPARGPPARASMN1; SMN2TSHRALDH1A1
SCHEMBL6959131 0.76 TDP1 (0.48) SMN1; SMN2TSHRALDH1A1KMT2AMEN1
SCHEMBL15261678 0.76 TSHR (0.43) PPARGPPARASMN1; SMN2TSHRKMT2A
SCHEMBL15262225 0.75 TSHR (0.39) PPARGPPARASMN1; SMN2TSHRALDH1A1
SCHEMBL2316112 0.74 TSHR (0.54) TSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PPARG 253/4885PPARA 259/4885SLC6A4 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.